-
Gilead Strikes Deal with Xilio Therapeutics for Tumor-Activated IL-12 Candidate
•
Gilead Sciences (NASDAQ: GILD) has announced an in-licensing agreement with fellow US biotechnology company Xilio Therapeutics (NASDAQ: XLO) to acquire an early-stage tumor-activated interleukin 12 (IL-12) for the treatment of solid tumors. Gilead will pay an initial sum of USD 43.5 million for the exclusive development and global commercialization rights…
-
Alphamab Oncology Reports 31.12% Revenue Growth in 2023 with Continued R&D Focus
•
Alphamab Oncology (HKG: 9966), a Chinese biopharmaceutical company, has released its financial performance and business updates for 2023. The company reported revenues of RMB 218.77 million (USD 27.6 million), marking a 31.12% increase year-on-year (YOY). Product sales accounted for RMB 195.55 million (USD 27 million), with a YOY growth of…
-
Bio-Thera Solutions Reports 54.86% YOY Revenue Growth in 2023, Led by Biosimilar Sales
•
Bio-Thera Solutions (SHA: 688177), a biopharmaceutical company headquartered in Guangzhou, has announced its financial results for 2023, reporting revenues of RMB 705 million (approximately USD 97.5 million), an increase of 54.86% year-on-year (YOY). This growth was largely driven by the sales of its biosimilar products: Qletli, a biosimilar version of…
-
Broncus Medical Inc. Reports 32% YOY Growth in 2023, Highlighted by Strength in China
•
Broncus Medical Inc. (HKG: 2216), a provider of precision intervention solutions for lung diseases with operations in Shanghai and Hangzhou, China, and San Jose and Seattle, United States, has released its financial report for 2023. The company reported product sales of USD 12.41 million for the period, marking a robust…
-
Jiangsu Hengrui’s SHR-A1921 Earns FDA Fast-Track Status for Platinum-Resistant Ovarian Cancer Therapies
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a distinguished pharmaceutical entity, has announced that it has been granted Fast-Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for its proprietary antibody-drug conjugate (ADC), SHR-A1921. This designation is for the treatment of platinum-resistant recurrent epithelial ovarian cancer, fallopian tube…
-
Hengrui Medicine Advances Clinical Trial for PD-L1 Inhibitor Combo in CLDN18.2 Positive Tumors
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company, has received approval from China’s National Medical Products Administration (NMPA) to initiate a Phase Ib/III clinical study. The study will evaluate the combination of Hengrui’s PD-L1 monoclonal antibody, adebrelimab (SHR-1316), with the antibody-drug conjugate (ADC) SHR-A1904 in patients with…
-
Allergan Aesthetics Launches SKINMEDICA in China, Targeting Booming Skincare Market
•
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced the market launch of its premium skincare product line, SKINMEDICA, in China. Known for its safety, efficacy, and clinical use backed by extensive medical research, SKINMEDICA is poised to offer Chinese consumers healthier and more confident skin solutions. This move…
-
InnoCare Pharma Initiates Phase Ib Study Combining ICP-189 with Furmonertinib for NSCLC
•
InnoCare Pharma (HKG: 9969, SHA: 688428), a biopharmaceutical company , has announced that the first patient has been dosed in a Phase Ib clinical study. The study is evaluating the combination of InnoCare’s SHP2 allosteric inhibitor, ICP-189, with the selective EGFR inhibitor furmonertinib for the treatment of advanced or metastatic…
